Risk Prediction of Death in Inpatient Adults With COVID-19 from Mexico

Ruth Aralí Martínez-Vega  
Universidad de Santander

Wang Jing  
Frederick National Laboratory for Cancer Research

Ana María Ortega-Villa  
National Institute of Allergy and Infectious Diseases

Oscar Manuel Delgado-Cuellar  
Hospital General de Zona No.1 Nueva Frontera

Victor Alonso Hemández-Hernández  
Hospital General de Zona No.1 Nueva Frontera

Julio Cesar Jan-Gómez  
Hospital General de Zona No.1 Nueva Frontera

Héctor Armando Rincón-León  
Instituto Mexicano del Seguro Social

Paul Constantino-Santiesteban  
Hospital General de Zona No.1 Nueva Frontera

Mariana Piedad García-Guerra  
Hospital Regional de Alta Especialidad Ciudad Salud

José Hiram Cetina-Díaz  
Hospital Regional de Alta Especialidad Ciudad Salud

José Manuel Pérez-Tirado  
Hospital Regional de Alta Especialidad Ciudad Salud

Omar Gómez-Cruz  
Hospital General Tapachula

Ima Yvonne Amaya-Larios  
Centro Educativo de Humanidades

Jose Ramos-Castañeda  
Instituto Nacional de Salud Pública

Sepúlveda-Delgado Jesús  
Hospital Regional de Alta Especialidad Ciudad Salud
Abstract

Background

There is substantial variation in COVID-19 lethality across countries. In addition, in countries with populations with extreme economic inequalities, such as Mexico, there are regional and local differences in risk factors for COVID-19 death. The goal of this study was to test the hypothesis that the risk of death in Mexican COVID-19 patients was associated with the time between symptom onset and hospitalization and/or with the healthcare site. Also, death prognostic models were developed.

Methods

The study included two COVID-19 inpatient cohorts, one prospective and one retrospective from Chiapas, Mexico. Demographic, clinical and laboratory variables were collected, and the diagnosis of SARS-CoV-2 infection was performed using RT-qPCR in samples collected seven days since symptom onset. The 30-day mortality, since symptom onset, was the outcome, and clinical variables at the first 48 hours of hospitalization were independent factors. Multivariate logistic regression analyses were conducted.

Results

Of the 392 patients included, 233 died (59.4%). The time between symptom onset and hospitalization, the healthcare site and sex were not related to the 30-day mortality. Three death prognostic models were developed (AUC between 0.726 and 0.807). Age, LDH, AST, and lymphocyte count were included in all models, OSI-WHO Classification (Non-invasive ventilation or high-flow oxygen, and mechanical ventilation with or without organ support/ECMO) and leukocyte count in two models, and diabetes and diarrhea in one model.

Conclusion

The population evaluated had underlying deteriorated health before COVID-19 compared with regional and country population. The factors that determine the COVID-19 mortality risk in a relatively healthy population are sex, age and comorbidities. However, as this study shows, when populations have underlying poor health, some of these factors lose their associations with mortality risk, and others become more important.

Introduction

The COVID-19 pandemic has imposed a significant challenge on national health systems at all levels. Although much information has been generated on the risk factors associated with the development of
severe illness and death due to COVID-19, the crucial challenge for the health systems is to avoid or decrease severe cases and mortality at the individual level.

There is substantial variation in lethality across countries. By the end of March 2021, the proportion of deaths per COVID-19 reported worldwide was close to 2.2%. Four out of the 12 countries that accounted for the most cases are located in the Americas, all with lethality near the worldwide average, USA (1.8%), Brazil (2.5%), Argentina (2.4%), and Colombia (2.6%). In contrast, during the same period, in Mexico the lethality was 9.0%, followed by Ecuador (5.2%), and Bolivia (4.5%) (1). Contrasting the number of tests per 1000 inhabitants and the COVID-19 lethality may suggest that the under-registration of total cases due to in country diagnostic test policies, may cause an over-registration of lethality since some of the countries that have the highest proportions of deaths per reported case of COVID-19 are those that apply fewer diagnostic tests per 1,000 inhabitants (2). For example, in the same time period the cumulative number of tests per 1,000 inhabitants was 1,095 in the USA, 239 in Colombia, 59 in Ecuador, and 42 in Mexico (3).

Notwithstanding, in countries with populations with extreme economic inequalities, such as Mexico, differences in risk factors appear to be similar to those reported worldwide (4, 5).

There are similarities in the factors associated with severe illness and death throughout studies carried out globally (6, 7), for example age, sex (8), and comorbidities such as diabetes, high blood pressure, and obesity (9). Systemic inflammation markers (e.g. increase in IL-6 or C-reactive protein), and metabolic markers (e.g. elevated ferritin, D-dimer, Lactate dehydrogenase, and creatinine) have also been associated with severe illness and death (10–12). Although various genetic markers have been associated with COVID-19 severity (13, 14), other variables like timeliness or quality of treatment (15) could influence the infection outcome. To the best of our knowledge, the latter has not been studied in detail. We analyzed a cohort of patients with a virologically confirmed diagnosis of COVID-19 in two secondary care centers in the state of Chiapas, Mexico, between March and September 2020. Our goal was to test the hypothesis that the deaths of COVID-19 patients are associated with time between symptom onset and hospitalization and/or with the site of admission.

**Methods**

**Study population and COVID-19 Tapachula study design**

This was an analysis of the study, “Clinical, genomic, transcriptomic, proteomic and metabolomic characterization of SARS-CoV-2 infection in Mexicans from the coastal region of the state of Chiapas” (Short name: COVID-19 Tapachula”) performed in the state of Chiapas, México between March and December 2020. The aim of the study was to characterize the clinical, biochemical, and genetic factors related to the disease progression of COVID-19 patients in the region. The study sites were located in Tapachula, the second most populated municipality of Chiapas, located 23 km north of the border with Guatemala. These sites provided attention to COVID-19 patients in the coast region of Chiapas, through two secondary-care hospitals.
The study included two cohorts, one prospective and one retrospective. The prospective cohort was enrolled at the “Clínica de enfermedades respiratorias COVID-19, Instituto de Seguridad Social de los Trabajadores del Estado de Chiapas (ISSTECHE)”, a secondary-care facility that provided attention to both insured and non-insured COVID-19 patients. The retrospective cohort was enrolled at the “Hospital General de Zona No.1 Nueva Frontera, Instituto Mexicano del Seguro Social (IMSS), Tapachula”, that provided attention to COVID-19 patients who were employed and insured.

The prospective cohort enrolled individuals who sought care for respiratory symptoms in the previous 7 days who fulfilled the following eligibility criteria: 1) Met the operational definition of a suspected case of COVID-19 in accordance with WHO/PAHO, for the presence of sudden onset of fever and cough; or sudden onset of three or more of the following symptoms: fever, cough, weakness or fatigue, headache, myalgia, sore throat, nasal cold, dyspnea, anorexia, nausea, vomiting, diarrhea or altered mental state; 2) had an available nasopharyngeal and/or pharyngeal swab for confirmation of SARS-CoV-2 infection; and 3) agreed to participate through informed consent form. Subjects with negative RT-qPCR from pharyngeal and/or nasopharyngeal swab were excluded from the final analysis. Clinical and biochemical data were collected through case report form (CRF).

The retrospective cohort enrolled patients who sought care for respiratory symptoms in the previous 7 days, who fulfilled the following eligibility criteria: 1) Met the operational definition of a suspected case of COVID-19 in accordance with WHO/PAHO; 2) had an available molecular test for confirmation of SARS-CoV-2 infection; 3) had available laboratory tests in the first 24 hours after hospital admission; and 4) had available clinical and biochemical data of admission and hospital stay. Subjects with concomitant confirmed influenza infection, and subjects with negative SARS-CoV-2 RT-qPCR were excluded. Clinical and biochemical data was collected retrospectively.

**Confirmation of SARS-CoV-2 infection**

The diagnosis of SARS-CoV-2 infection of the patients enrolled was performed with the CDC 2019-Novel Coronavirus (2019-nCoV) RT-qPCR following manufacturer indications, from pharyngeal and nasopharyngeal swabs collected seven days since symptom onset, with the modification published by Corman V.M et.al(16).

**Classification of severity of COVID-19**

Disease severity (maximum score reached for each patient in the first 48 hours after admission ) was defined by a modification of the ordinal scale of clinical improvement of the World Health Organization (OSI-WHO), which classifies severity of COVID-19 in eight categories(17): 1, ambulatory without limitation of activities; 2, ambulatory with limitation of activities, home oxygen requirement, or both; 3, hospitalized, does not require supplemental oxygen and no longer requires ongoing medical attention (used if hospitalization was extended for infection control reasons); 4, hospitalized, not requiring supplemental oxygen but requiring continuous medical care (COVID-19 related or other medical conditions); 5, hospitalized, requiring any supplemental oxygen; 6, hospitalized, requiring non-invasive ventilation or the
mechanical ventilation plus extracorporeal membrane oxygenation (ECMO); and 8, death. The ordinal score was calculated from CRF records (prospective cohort), or electronic records (retrospective cohort). We only considered categories 4 trough 7b because the participants were inpatients and alive at baseline.

Clinical and Laboratory variables

Clinical and biochemical data of enrolled subjects was collected from clinical records in CRF by sub-investigators at each site. The following data were collected: date of symptoms onset, main symptoms before hospital admission, symptoms at hospital admission, comorbidities, and OSI-WHO at hospital admission. Complete blood count (CBC) and blood chemistry including glucose, urea, ureic nitrogen, creatinine, serum electrolytes, and complete liver function tests were collected within 24 hours of hospital admission. The primary outcome considered for this study was 30-day mortality since symptom onset. For participants who survived and were discharged before day 30, the outcome was obtained through phone call.

Statistical Methods

Descriptive statistics of baseline biomarkers were calculated overall or by patient groups. To assess the difference between patient groups, Mann-Whitney, and Chi-square or Fisher's tests were used when appropriate. No multiplicity adjustments were performed. To investigate baseline biomarkers as predictors of risk of death due to COVID-19, univariate and multivariate logistic regressions were fitted using a training set (70% of the dataset – stratified by site). Model validation was performed using a test set (30% remaining). Statistically significant features at $\alpha = 0.05$ in the univariate logistic regression analysis were included in a stepwise model selection procedure minimizing either the AIC (Akaike information criterion) or BIC (Bayesian information criterion). The study site was forced to be always included in the stepwise selection process. Selected logistic regression models with similar model assessment criteria were further evaluated on the training set with leave-one-out cross validation, and test set using ROC curves (R pROC package). Sensitivity, specificity, PPV, and NPV of the models were compared. All three models were fitted on the entire dataset to obtain final estimates of risk of death. Analyses were conducted using R version 4.0.2.

Results

Of the 392 COVID-19 patients included during the study period, 233 died (59.4%). The majority of patients were hospitalized at the IMSS (82.4%), 67% were male, the median age was 60 years (range:18-96), the median time between symptom onset and hospital admission was 8 days (range:1-30), and the median hospitalization stay was 9 days (range:0-56), 45.2% of patients were in the fifth category of OSI-WHO (Oxygen by mask or nasal prongs), and approximately 7% of patients had mechanical ventilation or ventilation with organ support/ECMO each (Table 1).

Table 1. Baseline demographic characteristics of the COVID-19 patients, Tapachula, Mexico.
| Characteristic                                    | Overall n = 392 | Alive n = 159 | Dead n = 233 | p-value |
|--------------------------------------------------|----------------|---------------|--------------|---------|
| **Site of attention n (%)**                      |                |               |              | 0.028   |
| IMSS                                             | 323 (82.4)     | 139 (87.4)    | 184 (79)     |         |
| COVID Clinic ISSTECH                             | 69 (17.6)      | 20 (12.6)     | 49 (21)      |         |
| **Sex Male n (%)**                               | 263 (67.1)     | 107 (67.3)    | 156 (67)     | 0.943   |
| **Age years Mean (SD)**                          | 60 (13)        | 56 (13)       | 63 (12)      | <0.001  |
| **Days between symptom onset and admission Median (IQR)** | 8 (5 - 11)     | 8 (6 - 11)    | 7 (5 - 11)   | 0.581   |
| **Days of hospitalization**                      | 9 (5 - 16)     | 8 (4 - 14)    | 10 (5 - 16)  | 0.916   |
| **OSI-WHO Classification n (%)**                 |                |               |              | <0.001  |
| Hospitalized, no oxygen therapy (4)              | 13 (3.3)       | 11 (6.9)      | 2 (0.9)      |         |
| Oxygen by mask or nasal prongs (5)               | 177 (45.2)     | 98 (61.6)     | 79 (33.9)    |         |
| Non-invasive ventilation or high-flow oxygen (6) | 147 (37.5)     | 44 (27.7)     | 103 (44.2)   |         |
| Intubation and MV (7a)                           | 28 (7.1)       | 3 (1.9)       | 25 (10.7)    |         |
| MV + organ support/ECMO (7b)                     | 27 (6.9)       | 3 (1.9)       | 24 (10.3)    |         |
| **Fever n (%)**                                  | 339 (86.5)     | 144 (90.6)    | 195 (83.7)   | 0.046   |
| **Cough**                                        | 312 (79.6)     | 121 (76.1)    | 191 (82)     | 0.159   |
| **Dyspnea**                                      | 309 (79)       | 121 (76.1)    | 188 (81)     | 0.241   |
| **Myalgia**                                      | 238 (60.7)     | 107 (67.3)    | 131 (56.2)   | 0.027   |
| **Arthralgia**                                   | 228 (58.2)     | 101 (63.5)    | 127 (54.5)   | 0.075   |
| **Headache**                                     | 206 (52.6)     | 91 (57.2)     | 115 (49.4)   | 0.125   |
| **Deterioration of general condition**           | 167 (42.6)     | 68 (42.8)     | 99 (42.5)    | 0.956   |
| Characteristic          | Overall n = 392 | Alive n = 159 | Dead n = 233 | p-value |
|-------------------------|-----------------|---------------|--------------|---------|
| Chest pain              | 115 (29.3)      | 48 (30.2)     | 67 (28.8)    | 0.760   |
| Diarrhea                | 87 (22.2)       | 46 (28.9)     | 41 (17.6)    | **0.008** |
| Odynophagia             | 87 (22.2)       | 42 (26.4)     | 45 (19.3)    | 0.098   |
| Irritability            | 81 (20.7)       | 38 (23.9)     | 43 (18.5)    | 0.193   |
| Malaise                 | 83 (21.2)       | 43 (27)       | 40 (17.2)    | **0.020** |
| Rhinorrhea              | 70 (17.9)       | 31 (19.5)     | 39 (16.7)    | 0.485   |
| Dysgeusia/Ageusia\(^b\)| 46 (11.8)       | 20 (12.7)     | 26 (11.2)    | 0.653   |
| Anosmia                 | 46 (11.7)       | 21 (13.2)     | 25 (10.7)    | 0.456   |
| Polypnea                | 46 (11.7)       | 18 (11.3)     | 28 (12)      | 0.833   |
| Cyanosis                | 18 (4.6)        | 3 (1.9)       | 15 (6.4)     | **0.025** |
| Hypertension            | 161 (41.1)      | 60 (37.7)     | 101 (43.4)   | 0.267   |
| Diabetes                | 157 (40.1)      | 54 (34)       | 103 (44.2)   | **0.041** |
| Chronical kidney disease| 30 (7.7)        | 9 (5.7)       | 21 (9)       | 0.212   |

\(^a\)There was one missing value in death patients (n=232).

\(^b\)There was one missing value in alive patients (n=158).

Fever, cough and dyspnea were the most frequent symptoms, followed by nonspecific symptoms like myalgia, arthralgia, and headache. Upper respiratory symptoms including odynophagia, rhinorrhea, dysgeusia and anosmia were observed less frequently. Symptoms such as abdominal pain, hyporexia, vomit, nausea, dizziness, conjunctivitis, prechordalgia, polypnea, and cyanosis were observed in less than 10% of participants. Hypertension was the most frequent comorbidity, followed by diabetes mellitus and chronic kidney disease. Conditions such as gastrointestinal (4.3%), lung (3.6%), cardiovascular (3.6%), neurological (1.3%), and endocrine diseases (1%), cancer (2%) and stroke (1.5%) were infrequent (Table 1). The leukocyte count geometric mean was $11.9 \times 10^3$/cc with predominance of neutrophils, creatinine and lactate dehydrogenase (LDH) geometric means were above normal values with 1.3 mg/ml and 515 UI/L, respectively (Table 1). During hospitalization, most patients were treated with antibiotics, while steroids were only used in 20.2% of the patients (Table 2).
Table 2. Baseline blood test results and treatment of the COVID-19 patients, Tapachula, Mexico.
| Characteristic                              | n  | Overall              | Alive     | Dead     | p-value   |
|--------------------------------------------|----|----------------------|-----------|----------|-----------|
| Hemoglobin GMT (LCL-UCL)                   | 144/203 | 12.8 (12.6 - 13.1) | 12.9 (12.5 - 13.4) | 12.8 (12.5 - 13.1) | 0.052     |
| Red cell distribution width                | 140/198 | 14.3 (14.0 - 14.6)  | 13.9 (13.7 - 14.1) | 14.6 (14.1 - 15.1) | <0.001    |
| Leukocyte count x 10^3/cc                  | 144/202 | 11.9 (11.4 - 12.5)  | 10.6 (9.9 - 11.4)  | 13.0 (12.1 - 13.8) | <0.001    |
| Neutrophil count x 10^3/cc                 | 144/202 | 10.0 (9.4 - 10.6)   | 8.6 (7.9 - 9.3)    | 11.1 (10.3 - 11.9) | <0.001    |
| Lymphocyte count x 10^3/cc                 | 144/202 | 0.67 (0.61 - 0.73)  | 0.86 (0.77 - 0.96) | 0.56 (0.50 - 0.63) | <0.001    |
| NT/LYN ratio                               | 144/201 | 15 (13 - 17)        | 10 (9 - 12)        | 20 (17 - 23)       | <0.001    |
| Platelet count x 10^3/cc                   | 144/203 | 271 (258 - 284)     | 283 (265 - 303)    | 262 (245 - 280)    | 0.13      |
| Prothrombin time sec.                      | 114/174 | 13.2 (13.0 - 13.4)  | 12.9 (12.6 - 13.1) | 13.5 (13.2 - 13.8) | <0.001    |
| Activated partial thromboplastin time sec. | 112/170 | 34 (33 - 35)        | 33 (32 - 35)       | 34 (33 - 36)       | 0.4       |
| INR                                        | 114/174 | 1.12 (1.11 - 1.14)  | 1.09 (1.06 - 1.11) | 1.15 (1.13 - 1.18) | <0.001    |
| Glycemia mg/dL                             | 135/195 | 156 (146 - 167)     | 139 (126 - 153)    | 170 (155 - 185)    | <0.001    |
| Urea mg/dL                                 | 132/192 | 47 (43 - 52)        | 36 (32 - 42)       | 56 (50 - 63)       | <0.001    |
| Creatinine mg/ml                            | 134/193 | 1.3 (1.1 - 1.4)     | 1.0 (0.9 - 1.2)    | 1.5 (1.3 - 1.7)    | <0.001    |
| LDH UI/L                                   | 128/176 | 515 (487 - 545)     | 432 (400 - 467)    | 585 (543 - 631)    | <0.001    |
| Total bilirubin mg/ml                      | 134/186 | 0.64 (0.60 - 0.68)  | 0.64 (0.58 - 0.71) | 0.64 (0.59 - 0.69) | >0.9      |
| ALT UI/L                                   | 135/192 | 49 (45 - 53)        | 47 (42 - 52)       | 50 (45 - 56)       | 0.6       |
| AST UI/L                                   | 135/191 | 42 (38 - 45)        | 45 (40 - 51)       | 39 (35 - 44)       | 0.017     |
| Albumin g/dL                               | 122/162 | 3.0 (2.9 - 3.1)     | 3.2 (3.0 - 3.3)    | 2.9 (2.8 - 3.0)    | <0.001    |
| Sodium mEq/L                               | 127/180 | 134 (133 - 135)     | 135 (134 - 136)    | 134 (133 - 135)    | >0.9      |
In the univariate analysis, a significant difference between patients who died and those who survived was observed for the following variables: site, age, OSI-WHO classification, diabetes, and symptoms such as fever, myalgia, diarrhea, malaise, and cyanosis (Table 1). In addition, the red cell distribution width, leukocyte count, neutrophil count, prothrombin time, international normalized ratio (INR), glycemia, serum urea, serum creatinine, and LDH geometric means were higher in patients who died. Conversely, the lymphocyte count and aspartate aminotransferase (AST) geometric means were lower in this group (Table 2).

The death frequency was similar by sex ($p$-value=0.943) (Table 1, Figure 1). Malaise, polypnea and cyanosis were more frequent in women ($p<0.05$), while neutrophil count ($p=0.035$), Neutrophil/Lymphocyte (NT/LY) ratio ($p<0.001$), urea ($p=0.01$), creatinine ($p=0.003$), total bilirubin ($p<0.001$), the aminotransferases ($p<0.001$), and the potassium ($p=0.02$) geometric means were lower in women (Supplementary Table 1). Patients of this clinical cohort had a greater diabetes prevalence than the overall Mexican and Chiapas populations, and men had a greater hypertension prevalence (Supplementary Table 2).

The numbers above the bars represent the percentage of participants who died in each OSI-WHO classification group by sex. The percentage of death increases according to OSI-WHO classification in women and men.

The time between symptom onset and admission were not related to death ($p=0.581$), with median time between symptom onset and admission of 8 days in survived patients, and 7 days in participants who died. However, the lethality was different between the sites ($p=0.032$), and there was a significant difference observed in OSI/WHO classification between sites ($p=<0.001$) (Supplementary Table 3).

Three multivariate logistic regression models were developed to predict death (training set, n=276). Age, diarrhea, LDH, AST, and the lymphocyte count were present in the three models, while OSI-WHO classification, leukocyte count and NT/LYN ratio were variables selected in two models, and diabetes, platelet count and red cell distribution only selected in one model (Table 3).
| Characteristic                                      | OR (95%CI)       | M1 ORa (95%CI)   | M1a ORa (95%CI) | M2 ORa (95%CI) |
|----------------------------------------------------|------------------|------------------|------------------|---------------|
| **Age**                                            | 1.04 (1.02-1.06) | 1.04 (1.02-1.07) | 1.04 (1.02-1.07) | 1.05 (1.02-1.07) |
| **OSI-WHO Classification**                         |                  |                  |                  |               |
| Hospitalized, no oxygen therapy (4)                | Ref.             | Ref.             | Ref.             |               |
| Oxygen by mask or nasal prongs (5)                 | 5.97 (1.02-113)  | 4.67 (0.92-36.24) | 4.14 (0.83-32.60) |               |
| Non-invasive ventilation or high-flow oxygen (6)   | 16.2 (2.73-309)  | 8.8 (1.66-69.87) | 8.53 (1.65-68.70) |               |
| Intubation and MV (7a)                             | 112 (9.48-4,403) | 26.92 (3.29-324.38) | 32.15 (3.93-398.0) |               |
| MV + organ support/ECMO (7b)                       | 59.5 (6.50-1,511) | 22.41 (2.63-276.85) | 20.08 (2.46-242.46) |               |
| Diarrhea                                           | 0.47 (0.26-0.85) | 0.496 (0.24-1.01) | 0.55 (0.27-1.10) | 0.44 (0.22-0.85) |
| Diabetes                                           | 2.05 (1.23-3.46) | 1.97 (1.05-3.78) |                  |               |
| Log 2 LDH UI/L                                     | 2.33 (1.52-3.74) | 2.95 (1.66-5.49) | 3.05 (1.78-5.51) | 4.35 (2.63-7.60) |
| Log 2 AST UI/L                                     | 0.77 (0.60-0.98) | 0.58 (0.42-0.81) | 0.54 (0.40-0.74) | 0.58 (0.43-0.77) |
| Log2 Lymphocyte                                    | 0.62 (0.47-0.81) | 0.495 (0.31-0.82) | 0.50 (0.32-0.79) | 0.55 (0.41-0.72) |
| Log2 Leukocyte count                               | 1.69 (1.14-2.55) | 1.94 (1.10-3.44) | 1.77 (1.03-3.01) |               |
| NT/LYN ratio                                        | 1.02 (1.01-1.04) | 0.99 (0.98-1.01) | 0.99 (0.98-1.01) |               |
| Log2 Platelet count                                 | 0.62 (0.40-0.92) | 0.70 (0.42-1.17) |                  |               |
| Log 2 Red cell distribution width                  | 7.11 (1.36-55.2) | 7.66 (1.13-87.66) |                  |               |
The M1a model had the highest sensitivity in the training set (n=276), however the AUCs (Figure 2) were similar among the three models (≈0.8). The M1 model had the highest sensitivity in the test set (n=116) with no difference in the AUC among the three models (Table 4). Focusing on M1, we found an association between the OSI-WHO classification and the risk of death, with higher odds of a participant dying for participants with non-invasive ventilation or high-flow oxygen, intubation or on mechanical ventilation, and mechanical ventilation or ECMO (when compared to no oxygen therapy). We found higher odds of death for participants with diabetes mellitus, increases in Log2 LDH, and Log2 Leukocyte count, and lower odds of death with increases in Log2 AST and Log2 Lymphocytes (Table 3).

Table 4. Model performance in treating set (Tr, n=276) and test set (T, n=116).

| Model      | Accuracy | Sensitivity | Specificity | PPV    | NPV    | AUC (95%CI)          |
|------------|----------|-------------|-------------|--------|--------|----------------------|
| Model M1 (Tr) | 0.756    | 0.792       | 0.706       | 0.792  | 0.706  | 0.807 (0.745 - 0.869) |
| Model M1a (Tr) | 0.761    | 0.825       | 0.671       | 0.780  | 0.731  | 0.806 (0.744 - 0.868) |
| Model M2 (Tr) | 0.751    | 0.783       | 0.706       | 0.790  | 0.698  | 0.791 (0.726 - 0.856) |
| Model M1 (T)  | 0.762    | 0.818       | 0.700       | 0.750  | 0.778  | 0.764 (0.671 - 0.857) |
| Model M1a (T) | 0.744    | 0.737       | 0.759       | 0.857  | 0.595  | 0.726 (0.632 - 0.820) |
| Model M2 (T)  | 0.767    | 0.774       | 0.758       | 0.837  | 0.676  | 0.756 (0.664 - 0.849) |

Discussion

COVID-19 is a disease that can have a fatal outcome. Lethality in hospitalized patients depends on features, including viral (infection rate, viral load, virulence), individual (genetic factors, age, sex, race, ethnicity, comorbidities), and health system factors (epidemiological surveillance systems, hospital resources, and access to health services). Factors related to the health system play a fundamental role in guaranteeing the opportunity and quality of care for patients with COVID-19 who require hospitalization. Social determinants of health have contributed to the hospital lethality rates from...
COVID-19 observed in different countries throughout the pandemic. Globally, the lethality observed by COVID-19 is less than 3%, although in countries like Mexico, it can reach values close to 10% (3). In this work, a lethality of 59.4% was observed in the period from March to September 2020, much higher than that reported globally for this type of population globally (19, 20), and than the COVID-19 lethality in Mexico in the same period (11% (21)). In Mexico, two studies carried out in tertiary hospitals in different geographical locations reported a lethality of 30.1% (4, 22).

The excess lethality observed in the present study may have several explanations, for example local factors in the health system. In this study, participants were enrolled in two public health institutions that serve different populations. The IMSS is a second-level federal public hospital that treated insured patients and had 180 beds available which reached a maximum occupancy of 130 beds and 75 mechanically ventilated patients. In contrast, the COVID-19 respiratory disease clinic is a public clinic-hospital managed by the Chiapas Ministry of Health, adapted to serve COVID-19 patients without any type of social security or healthcare coverage, had 20 enabled beds during the study period, and repeatedly reached maximum bed and intubation capacity. The saturation of both hospitals during the first outbreak in the state of Chiapas, as well as the capacity, infrastructure and medical personnel available to care for patients, could have directly influenced the observed lethality. In the univariate analysis, a statistically significant difference was found in the lethality between the two recruitment sites (IMSS 57% vs ISSTECH 79%; p = 0.028). However, in multivariate analyses this association was lost when the analysis was adjusted by individual conditions such as age, diabetes, and clinical variables. In Mexico, it has been estimated that lethality is higher (2 to 3 times) in public hospitals when compared to private hospitals (23). Likewise, delay in attention is thought to be a variable associated with COVID-19 lethality (24).

COVID-19 mortality risk has been consistently associated globally with certain biochemical markers, such as leukocyte and lymphocyte count, concentrations of proinflammatory interleukins and growth factors, levels of LDH, ferritin, and D-dimer (25, 26). Although in the univariate analysis several markers were consistent with associations previously reported in the literature (Table 2), when evaluated in the multivariate analysis, only age, diabetes, LDH and leukocyte count were associated with an increased chance of dying (Table 3). In general terms, our patients did not show a pattern of biochemical markers that explained the observed excess lethality.

Another contributing factor to the observed excess lethality was the infection severity at admission defined by the OSI-WHO, which assesses a patient’s need for supplemental oxygen, including mechanical ventilation and additional support. The need for the use of supplemental oxygen as a risk factor for death from COVID-19 has been discussed without reaching a consensus (27, 28). In our population, we analyzed the OSI-WHO scale (29) in the first 48 hours after hospital admission as a possible marker of mortality risk, and found a statistically significant association. The greater the need for oxygen, the greater the risk of dying from COVID-19 (Tables 1 and 3). This finding shows that patients who developed respiratory failure in the first 48 hours after admission had a higher risk of death, regardless of any other factor.
Unexpectedly, the male sex, which is one of the risk factors most commonly associated with mortality risk from COVID-19 globally (30, 31), was not a risk factor in our population (Table 1). We believe that the lack of differences in mortality by sex was due to the underlying deteriorated health of this population. For example, both men and women over 40 years of age (more than 94% of our cohort) had a higher prevalence of diabetes (W:37.2%, M:41.4%) than the population of the state of Chiapas (W:12.9%-18.2%, M:10.9%-13.3%), and than the Mexican population (W:14.3%-27.4%, M:11.9%-22.8%) of the same age groups (Supplementary table 2). Another example is renal insufficiency was higher in our study (W:7.0%, M:8.0%), than in Chiapas (W:1.4%-2.4%, M:0.7-1.3%) and Mexico (W:0.9%-2.4%, M:0.8%-2.1%) (Supplementary table 2)(32).

A limitation of this study is the lack of information on some variables such as oximetry, arterial gases, D-dimer, and weight/height to determine obesity, which have been found to be associated with death in other studies. Also, the small sample size limits the accuracy of association measure estimates and model performance.

**Conclusions**

The factors that determine the COVID 19 mortality risk in a relatively healthy population are sex, age and comorbidities. However, as this study shows, when populations have underlying poor health, some of these factors lose their associations with risk, and others become more important. Further work is needed to determine the importance of this observation which if corroborated, may be a crucial element in public policy and epidemic outbreak management.

**Abbreviations**

AIC: Akaike information criterion.
AST: Aspartate aminotransferase.
AUC: Area under the ROC Curve.
BIC: Bayesian information criterion.
CBC: Complete blood count.
CDC: Centers for Disease Control and Prevention
COVID-19: Coronavirus disease 2019.
CRF: Case report form.
ECMO: Extracorporeal membrane oxygenation.
INR: International normalized ratio.

ISSTECH: Instituto de Seguridad Social de los Trabajadores del Estado de Chiapas.

LDH: Lactate dehydrogenase.

NT/LY ratio: Neutrophil/Lymphocyte ratio.

OSI-WHO Classification: Ordinal scale of clinical improvement of the World Health Organization.

PPV: Positive predictive value.

NPV: Negative predictive value.

ROC: Receiver operating characteristic curve.

RT-qPCR: Quantitative reverse transcription polymerase chain reaction.

WHO/PAHO: World Health Organization/Pan American Health Organization.

Declarations

Ethics approval and consent to participate

The study was carried out in accordance with principles of the Helsinki Declaration. The study protocol of the prospective cohort was evaluated and approved by the ethics and research committee of the Hospital Regional de Alta Especialidad Ciudad Salud (Id: 08/2020) and the research and ethics committee of the Ministry of Health of the state of Chiapas (Id: EADIS-010-2020). Participation was voluntary, and specific procedures were presented in writing in informed consent. All participants gave their permission or, if they were not in physical conditions, legal representatives authorized their participation by signing the informed consent.

On the other hand, the study protocol of the retrospective cohort was evaluated and approved by the National Scientific Research Committee of the Mexican Institute of Social Security (Id: R-2020-785-182). The requirement of the informed consent was waived by the National Scientific Research Committee of the Mexican Institute of Social Security (Id: R-2020-785-182), because of that, the research team did not obtain the informed consent form. The data collected from each patient was captured in electronic databases and managed as confidential.

Consent for publication

Not applicable.

Availability of data and materials
All generated analysis during this study is included in this published article and its supplementary information files. The data that support the findings of this study are available from Research Division of the Hospital Regional de Alta Especialidad Ciudad Salud, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Research Division of the Hospital Regional de Alta Especialidad Ciudad Salud.

**Competing interests**

The authors declare that they have no competing interest.

**Funding**

The study has been funded in whole or in part by the Consejo Nacional de Ciencia y Tecnología (CONACyT) through the Programa de Apoyos para actividades científicas, tecnológicas y de innovación (Project Id 312321) in 2020; and in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N910D00024, Task Order No. 75N91019F00130. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funding agencies did not participate in the design of the study and collection, analysis, interpretation of data, or in writing the manuscript.

**Authors’ contributions**

RAM-V: Analysis and interpretation of data. Drafting the work. Final approval of the version to be published.

JW: Analysis and interpretation of data. Drafting the work. Final approval of the version to be published.

AMO-V: Analysis and interpretation of data. Drafting the work. Final approval of the version to be published.

OMD-C: Acquisition of data. Revising the work critically for important intellectual content. Final approval of the version to be published.

VAH-H: Acquisition of data. Acquisition of data. Revising the work critically for important intellectual content. Final approval of the version to be published.

JCJ-G: Acquisition of data. Revising the work critically for important intellectual content. Final approval of the version to be published.

HAR-L: Acquisition of data. Revising the work critically for important intellectual content. Final approval of the version to be published.
PC-S: Acquisition of data. Revising the work critically for important intellectual content. Final approval of the version to be published.

MPG-G: Acquisition of data. Revising the work critically for important intellectual content. Final approval of the version to be published.

JHC-D: Acquisition of data. Revising the work critically for important intellectual content. Final approval of the version to be published.

JMP-T: Acquisition of data. Revising the work critically for important intellectual content. Final approval of the version to be published.

OG-C: Acquisition of data. Revising the work critically for important intellectual content. Final approval of the version to be published.

IYA-L: Analysis and interpretation of data. Revising the work critically for important intellectual content. Final approval of the version to be published.

JR-C: Design of the work. Interpretation of data. Drafting the work. Final approval of the version to be published.

JS-D: Conception and design of the work. Interpretation of data. Conception or design of the work. Drafting the work. Final approval of the version to be published.

Acknowledgements

Not applicable.

References

1. WHO. WHO Coronavirus Disease (COVID-19) Dashboard Geneva2020 [Available from: https://covid19.who.int/.

2. Gaye B, Fanidi A, Jouven X. Denominator matters in estimating COVID-19 mortality rates. Eur Heart J. 2020;41(37):3500.

3. Oxford Uo. Our World in Data Oxford UK2020 [Available from: https://ourworldindata.org/coronavirus-data-explorer?zoomToSelection=true&time=earliest..latest&country=USA~CAN~BRA~FRA~BOL~ECU~MEX~ARG~COL&region=World&testsMetric=true&interval=total&perCapita=true&smoothing=0&pickerMetric=location&pickerSort=asc.

4. Ruiz-Quinonez JA, Guzman-Priego CG, Nolasco-Rosas GA, Tovilla-Zarate CA, Flores-Barrientos OI, Narvaez-Osorio V, et al. Features of patients that died for COVID-19 in a hospital in the south of Mexico: A observational cohort study. PLoS One. 2021;16(2):e0245394.
5. Olivas-Martinez A, Cardenas-Fragoso JL, Jimenez JV, Lozano-Cruz OA, Ortiz-Brizuela E, Tovar-Mendez VH, et al. In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. PLoS One. 2021;16(2):e0245772.

6. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2020.

7. Prado-Galbarro FJ, Sanchez-Piedra C, Gamino-Arroyo AE, Cruz-Cruz C. Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients. Public Health. 2020;189:66-72.

8. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020.

9. Gasmi A, Peana M, Pivina L, Srinath S, Gasmi Benahmed A, Semenova Y, et al. Interrelations between COVID-19 and other disorders. Clin Immunol. 2021;224:108651.

10. Tjendra Y, Al Mana AF, Espejo AP, Akgun Y, Millan NC, Gomez-Fernandez C, et al. Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers. Arch Pathol Lab Med. 2020.

11. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med. 2020;58(7):1135-8.

12. Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020;8:37.

13. Elhabyan A, Elyaacoub S, Sanad E, Abukhadra A, Elhabyan A, Dinu V. The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review. Virus Res. 2020;289:198163.

14. Zeberg H, Paabo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 2020.

15. Macias Gil R, Marcelin JR, Zuniga-Blanco B, Marquez C, Mathew T, Piggott DA. COVID-19 Pandemic: Disparate Health Impact on the Hispanic/Latinx Population in the United States. J Infect Dis. 2020;222(10):1592-5.

16. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3).

17. WHO. WHO R&D Blueprint novel Coronavirus

18. COVID-19 Therapeutic Trial Synopsis: World Health Organization; 2020 [Available from: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf.

19. Madahar P, Wunsch H, Jha P, Slutsky AS, Brodie D. Trends in COVID-19-related in-hospital mortality: lessons learned from nationwide samples. Lancet Respir Med. 2021.
20. Ranzani OT, Bastos LSL, Gelli JGM, Marchesi JF, Baião F, Hamacher S, et al. Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021.

21. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345-55.

22. UNAM. Plataforma de información geográfica de la UNAM sobre COVID-19 en México Mexico2021 [Available from: https://covid19.ciga.unam.mx/]

23. Ortiz-Brizuela E, Villanueva-Reza M, Gonzalez-Lara MF, Tamez-Torres KM, Roman-Montes CM, Diaz-Mejia BA, et al. Clinical and Epidemiological Characteristics of Patients Diagnosed with Covid-19 in a Tertiary Care Center in Mexico City: A Prospective Cohort Study. Rev Invest Clin. 2020;72(4):252-8.

24. Najera H, Ortega-Avila AG. Health and Institutional Risk Factors of COVID-19 Mortality in Mexico, 2020. Am J Prev Med. 2021;60(4):471-7.

25. Czeisler ME, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, et al. Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns - United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(36):1250-7.

26. Chidambaram V, Tun NL, Haque WZ, Majella MG, Sivakumar RK, Kumar A, et al. Factors associated with disease severity and mortality among patients with COVID-19: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0241541.

27. Mehta AA, Haridas N, Belgundi P, Jose WM. A systematic review of clinical and laboratory parameters associated with increased severity among COVID-19 patients. Diabetes Metab Syndr. 2021;15(2):535-41.

28. Chang R, Elhusseiny KM, Yeh YC, Sun WZ. COVID-19 ICU and mechanical ventilation patient characteristics and outcomes-A systematic review and meta-analysis. PLoS One. 2021;16(2):e0246318.

29. Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A, et al. Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis. Am J Respir Crit Care Med. 2021;203(1):54-66.

30. WHO. COVID-19 Therapeutic Trial Synopsis. Geneva, Switzerland: R&DBlueprint; 2020. Available from: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf.

31. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317.

32. Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020;12(13):12493-503.
Figure 1

Percentage of death by OSI-WHO classification and sex (n=392).
Figure 2

ROC for COVID-19 mortality in the Training Set

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• Additionalfile.docx